ERA 2025: Pegcetacoplan Shows Strong Kidney Benefit in Rare Diseases
Pegcetacoplan demonstrated a significant reduction in proteinuria and signs of kidney damage in patients with C3G or IC-MPGN and nephrotic-range proteinuria, according to VALIANT Phase 3 results.